Latest Aktis Oncology News & Updates

See the latest news and media coverage for Aktis Oncology. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Aktis Oncology

Biotechnology company developing targeted alpha radiopharmaceuticals

aktisoncology.com
Company type
Public company
Number of employees
100–200
Industry
Pharmaceuticals

Last updated

Latest news about Aktis Oncology

In short: Aktis Oncology raised $318 million in a 2026 IPO and reported positive first-in-human imaging data for its lead radiopharmaceutical candidate.

Company announcements

Aktis Oncology

Aktis Oncology has received FDA Fast Track designation for AKY-1189

It is for treating locally advanced or metastatic urothelial cancer after prior therapies. A Phase 1b trial is ongoing.

Unlock all announcements with a

Media coverage

WFMZ

Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed...

Unlock all articles with a

Never miss news about Aktis Oncology

Track Aktis Oncology and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.